Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Country Average (16), the stock would be worth $209.17 (3 550% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.4 | $5.73 |
0%
|
| Country Average | 16 | $209.17 |
+3 550%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$-7.1m
|
/ |
Jan 2026
$-16.3m
|
= |
|
|
$-7.1m
|
/ |
Dec 2026
$-21.2m
|
= |
|
|
$-7.1m
|
/ |
Dec 2027
$-1.4m
|
= |
|
|
$-7.1m
|
/ |
Dec 2028
$42m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IL |
Q
|
Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
|
9.3m USD | 0.4 | -0.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 361.7 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
175.6B USD | 24.8 | 26.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.4B USD | 26 | 34.2 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 16.3 | 15.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 25.4 | -118.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.3B USD | 22.1 | 25.5 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.5B USD | 39 | 48 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.3B USD | 17.3 | 20.4 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 24.9 | 30.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.7 |
| Median | 16 |
| 70th Percentile | 23.8 |
| Max | 877.3 |
Other Multiples
Quoin Pharmaceuticals Ltd
Glance View
Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
